0000899243-15-003061.txt : 20150813
0000899243-15-003061.hdr.sgml : 20150813
20150813163059
ACCESSION NUMBER: 0000899243-15-003061
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150803
FILED AS OF DATE: 20150813
DATE AS OF CHANGE: 20150813
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rolfe Lindsey
CENTRAL INDEX KEY: 0001650504
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 151051068
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2015-08-03
0
0001466301
Clovis Oncology, Inc.
CLVS
0001650504
Rolfe Lindsey
C/O CLOVIS ONCOLOGY, INC.,
2525 28TH STREET, SUITE 100
BOULDER
CO
80301
0
1
0
0
See remarks
Employee stock option (right to buy)
3.08
2020-04-07
Common Stock
31034
D
Employee stock option (right to buy)
3.28
2021-03-01
Common Stock
17241
D
Employee stock option (right to buy)
24.74
2022-03-01
Common Stock
30000
D
Employee stock option (right to buy)
21.81
2023-03-01
Common Stock
40000
D
Employee stock option (right to buy)
73.98
2024-01-10
Common Stock
17500
D
Employee stock option (right to buy)
78.38
2024-02-27
Common Stock
35000
D
Employee stock option (right to buy)
79.05
2025-03-02
Common Stock
12500
D
Employee stock option (right to buy)
85.65
2025-08-03
Common Stock
35000
D
The option vested as to 25% of the shares on April 1, 2011 and the remainder vested in substantially equal installments over the 36 months immediately following such date.
The option vested as to 25% of the shares on March 1, 2012 and the remainder vested in substantially equal installments over the 36 months immediately following such date.
The option is immediately exercisable as to both vested and unvested shares. The option vested as to 25% of the shares on March 1, 2013 and the remainder vest in substantially equal installments over the 36 months immediately following such date. To the extent the reporting person exercises the option as to unvested shares, the reporting person will receive restricted shares that will vest in accordance with the vesting schedule for the option.
The option vested as to 25% of the shares on March 1, 2014 and the remainder vest in substantially equal installments over the 36 months immediately following such date.
The option vested as to 25% of the shares on January 10, 2015 and the remainder vest in substantially equal installments over the 36 months immediately following such date.
The option vested as to 25% of the shares on February 27, 2015 and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
The option shall vest as to 25% of the shares on March 2, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
The option shall vest as to 25% of the shares on August 3, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance
/s/ Lindsey Rolfe
2015-08-13